Miniaturized implantable cardiac monitor with a long sensing vector (BIOMONITOR III): Insertion procedure assessment, sensing performance, and home monitoring transmission success.

Cardiac arrhythmia Implantable cardiac monitor Implantable loop recorder Remote monitoring Syncope

Journal

Journal of electrocardiology
ISSN: 1532-8430
Titre abrégé: J Electrocardiol
Pays: United States
ID NLM: 0153605

Informations de publication

Date de publication:
Historique:
received: 27 02 2020
revised: 26 03 2020
accepted: 07 04 2020
pubmed: 4 5 2020
medline: 22 6 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

Implantable Cardiac Monitors (ICMs) are used for long-term monitoring of arrhythmias. BIOMONITOR III is a novel ICM with a miniaturized profile, long sensing vector due to a flexible antenna, simplified implantation with a dedicated insertion tool for pocket formation and ICM placement in a single step, and daily automatic Home Monitoring (HM) function. In 47 patients undergoing BIOMONITOR III insertion for any ICM indication, 16 investigators at 10 Australian sites assessed handling characteristics of the insertion tool, R-wave amplitudes, noise burden, P-wave visibility, and HM transmission success. Patients were followed for 1 month. All 47 attempted insertions were successful. Median time from skin incision to removal of the insertion tool after ICM insertion was 39 s (IQR 19-65) and to wound closure and cleaning was 4.7 min (IQR 3.5-7.8). All aspects of the insertion tool were rated as "good" or "excellent" in ≥97.9% and "fair" in ≤2.1% of patients, except for "force needed for tunnelling" (91.5% good/excellent, 8.5% fair). Based on HM data, R-waves in the first month were stable at 0.70 ± 0.37 mV. Median noise burden (disabling automatic rhythm evaluation) was 0.19% (IQR 0.00-0.93), equivalent to 2.7 min (IQR 0.0-13.4) per day. In HM-transmitted ECG strips with regular sinus rhythm, P-waves were visible in 89 ± 24% of heart cycles. Patient-individual automatic Home Monitoring transmission success was 98.0% ± 5.5%. The novel ICM performed well in all aspects studied, including fast insertion, reliable R-wave sensing, good P-wave visibility, and highly successful HM transmissions.

Sections du résumé

BACKGROUND
Implantable Cardiac Monitors (ICMs) are used for long-term monitoring of arrhythmias. BIOMONITOR III is a novel ICM with a miniaturized profile, long sensing vector due to a flexible antenna, simplified implantation with a dedicated insertion tool for pocket formation and ICM placement in a single step, and daily automatic Home Monitoring (HM) function.
METHODS
In 47 patients undergoing BIOMONITOR III insertion for any ICM indication, 16 investigators at 10 Australian sites assessed handling characteristics of the insertion tool, R-wave amplitudes, noise burden, P-wave visibility, and HM transmission success. Patients were followed for 1 month.
RESULTS
All 47 attempted insertions were successful. Median time from skin incision to removal of the insertion tool after ICM insertion was 39 s (IQR 19-65) and to wound closure and cleaning was 4.7 min (IQR 3.5-7.8). All aspects of the insertion tool were rated as "good" or "excellent" in ≥97.9% and "fair" in ≤2.1% of patients, except for "force needed for tunnelling" (91.5% good/excellent, 8.5% fair). Based on HM data, R-waves in the first month were stable at 0.70 ± 0.37 mV. Median noise burden (disabling automatic rhythm evaluation) was 0.19% (IQR 0.00-0.93), equivalent to 2.7 min (IQR 0.0-13.4) per day. In HM-transmitted ECG strips with regular sinus rhythm, P-waves were visible in 89 ± 24% of heart cycles. Patient-individual automatic Home Monitoring transmission success was 98.0% ± 5.5%.
CONCLUSIONS
The novel ICM performed well in all aspects studied, including fast insertion, reliable R-wave sensing, good P-wave visibility, and highly successful HM transmissions.

Identifiants

pubmed: 32361086
pii: S0022-0736(20)30107-2
doi: 10.1016/j.jelectrocard.2020.04.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

118-125

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest JM, RW, UM, PG, RP, TL, AC, PI and SP have received honoraria and/or non-financial support from Biotronik in the context of this study. JS is a full-time employee of Biotronik. PG, DHL and UW has received honoraria from Biotronik outside the context of this study.

Auteurs

Justin A Mariani (JA)

The Alfred Hospital, 55 Commercial Rd, Melbourne, VIC 3004, Australia; Central Clinical School, Monash University, 99 Commercial Rd, Melbourne, VIC 3004, Australia. Electronic address: j.mariani@alfred.org.au.

Rukshen Weerasooriya (R)

University of Western Australia, Department of Medicine, Crawley, WA 6000, Australia. Electronic address: rukshen@afablationclinic.com.au.

Olivier van den Brink (O)

The Alfred Hospital, 55 Commercial Rd, Melbourne, VIC 3004, Australia; Central Clinical School, Monash University, 99 Commercial Rd, Melbourne, VIC 3004, Australia. Electronic address: olivier.vandenbrink@isp.net.au.

Uwais Mohamed (U)

St Vincent's Hospital, 41 Victoria Parade, Fitzroy, VIC 3065, Australia. Electronic address: Uwais.mohamed@svha.org.au.

Paul A Gould (PA)

The University of Queensland, and Department of Cardiology, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, QLD 4102, Australia. Electronic address: paul.gould2@health.qld.gov.au.

Rajeev K Pathak (RK)

Australian National University and The Canberra Hospital, Yamba Dr, Canberra, ACT 2605, Australia. Electronic address: rajeev.pathak@act.gov.au.

Tina Lin (T)

GenesisCare Victoria, 5/126 Wellington Pde, East Melbourne, VIC 3002, Australia. Electronic address: tina.lin@genesiscare.com.

Andre Conradie (A)

GenesisCare, Friendly Society Private Hospital, 19-23 Bingera Street, Bundaberg, QLD 4670, Australia. Electronic address: andre.conradie@genesiscare.com.

Peter Illes (P)

Sydney Adventist Hospital, 185 Fox Valley Road, Wahroonga, NSW 2076, Australia.

Stephen Pavia (S)

GenesisCare, The Wesley Hospital, 30 Chasely St, Auchenflower, QLD 4066, Australia. Electronic address: stephen.pavia@genesiscare.com.

Kushwin Rajamani (K)

University of Western Australia, Department of Medicine, Crawley, WA 6000, Australia.

Sam Lovibond (S)

The Alfred Hospital, 55 Commercial Rd, Melbourne, VIC 3004, Australia; Central Clinical School, Monash University, 99 Commercial Rd, Melbourne, VIC 3004, Australia.

Ian Matthews (I)

St Vincent's Hospital, 41 Victoria Parade, Fitzroy, VIC 3065, Australia. Electronic address: ian.matthews@svha.org.au.

David DiFiore (D)

GenesisCare, Friendly Society Private Hospital, 19-23 Bingera Street, Bundaberg, QLD 4670, Australia. Electronic address: david.difiore@genesiscare.com.

Deepak Arumugam (D)

GenesisCare, The Wesley Hospital, 30 Chasely St, Auchenflower, QLD 4066, Australia. Electronic address: deepak.arumugam@genesiscare.com.

Jürgen Schrader (J)

Biotronik SE & Co. KG, Woermannkehre 1, 12359 Berlin, Germany. Electronic address: juergen.schrader@biotronik.com.

Dennis H Lau (DH)

Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia. Electronic address: dennis.h.lau@adelaide.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH